FY2029 EPS Estimates for uniQure Decreased by HC Wainwright

uniQure N.V. (NASDAQ:QURE) – Equities researchers at HC Wainwright dropped their FY2029 earnings estimates for uniQure in a research note issued on Wednesday, November 12th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings per share of $3.85 for the year, down from their prior forecast of $3.90. HC Wainwright currently has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share.

Other research analysts have also recently issued research reports about the stock. The Goldman Sachs Group reduced their target price on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, October 8th. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, August 2nd. Leerink Partners decreased their target price on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday. Finally, William Blair reaffirmed a “market perform” rating on shares of uniQure in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $64.42.

uniQure Stock Up 0.4%

uniQure stock traded up $0.13 during midday trading on Thursday, reaching $30.25. The stock had a trading volume of 738,083 shares, compared to its average volume of 2,231,956. The stock has a market capitalization of $1.66 billion, a P/E ratio of -7.71 and a beta of 0.59. The firm’s fifty day simple moving average is $42.80 and its 200-day simple moving average is $24.54. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. uniQure has a 1-year low of $5.50 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%.

Insider Buying and Selling at uniQure

In other news, Director Robert Gut sold 31,434 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total value of $856,890.84. Following the transaction, the director owned 40,145 shares in the company, valued at approximately $1,094,352.70. The trade was a 43.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of the stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the completion of the sale, the chief executive officer owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This represents a 25.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 314,560 shares of company stock valued at $12,362,568. 4.79% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently made changes to their positions in the business. Private Trust Co. NA bought a new position in uniQure during the third quarter valued at about $28,000. Jones Financial Companies Lllp boosted its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the period. Knott David M Jr purchased a new position in shares of uniQure in the third quarter valued at $117,000. Westfield Capital Management Co. LP purchased a new stake in uniQure during the 3rd quarter worth about $223,000. Finally, Ballentine Partners LLC bought a new position in uniQure in the 3rd quarter worth about $301,000. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.